GeoVax Labs stockholders approved a proposal to effect a reverse stock split of its common stock at a ratio determined by the Board, ranging from 1-for-10 to 1-for-25. The vote passed with 3,484,374 shares in favor and 828,802 against. Separately, shareholders approved the issuance of up to 11,395,256 common shares upon exercise of warrants issued under a prior inducement program. GeoVax Labs is a biotechnology company focused on vaccine development.
